Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 30Lymphoma, Follicular 9Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Lymphoma, Non-Hodgkin 5Leukemia, Lymphocytic, Chronic, B-Cell 4Neoplasms 3Smoldering Multiple Myeloma 2Myelodysplastic Syndromes 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Plasma Cell 2Leukemia, Myelomonocytic, Chronic 2Burkitt Lymphoma 2Recurrence 1Neoplasms, Plasma Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1GATA2 Deficiency 1Anemia, Refractory, with Excess of Blasts 1Anemia 1

Interventions

Azacitidine 2venetoclax 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Vorinostat 1Thiotepa 1Tacrolimus 1Methotrexate 1Lenalidomide 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
GATA2 Deficiency × Lenalidomide × 30 days × Clear all
NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡